Drug Trial News

RSS

Researchers receive $14 million grant to study the effectiveness of hydrocephalus treatment

Patients diagnosed with idiopathic normal pressure hydrocephalus (iNPH), a type of brain swelling most commonly seen in older adults — and for which the underlying cause is unknown — are typically treated by surgically installing a shunt (drain) to remove the excess fluid associated with the condition.

26 Aug 2021

Could soluble CD24 offer some hope against severe COVID-19?

A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.

26 Aug 2021

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

A combination of metformin and chemoradiation in patients with locally advanced non-small cell lung cancer (LA-NSCLC) was not found to add survival benefit in the NRG Oncology clinical trial NRG-LU001. These results were recently published in JAMA Oncology.

25 Aug 2021

New clinical trial to test third dose of COVID-19 vaccine for immunocompromised people

A new clinical trial to determine whether a third dose of vaccine will improve the immune response for people who have weakened immune systems is launching in the UK.

24 Aug 2021

Antiviral strategy using synthetic peptoid has promising implications for fighting infection

Scientists have manufactured a synthetic form of peptide to combat viral infections, with tests already conducted on HSV-1 as well as SARS-CoV-2.

24 Aug 2021

Lipid-lowering drug TriCor dramatically cuts treatment time for severe COVID-19 patients

The SARS-CoV-2 virus has infected over 165 million people worldwide causing nearly 3.5 million deaths. Recent vaccination efforts have been hindered by multiple coronavirus variants that challenge current vaccines.

23 Aug 2021

Phase I clinical study evaluates safety and pharmacokinetics of ExeVir's COVID-19 neutralizing antibody

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

19 Aug 2021

Children’s Hospital Colorado helps prove safety and efficacy of CF treatment in younger pediatric patients

Researchers at the Children's Hospital Colorado Breathing Institute, the largest pediatric cystic fibrosis (CF) clinical care center in the U.S., participated in the pivotal international multi-center Phase 3 clinical trial, sponsored by Vertex Pharmaceuticals Incorporated, leading to FDA approval of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor), a highly effective CF treatment, for patients ages 6 through 11 who have at least one copy of the F508del mutation.

17 Aug 2021

New clinical trial investigates aspirin as part of new treatment for triple negative breast cancer

An innovative new study is trialing whether giving aspirin, commonly used as pain relief, alongside immunotherapy drug avelumab could improve its effectiveness for people affected by breast cancer.

17 Aug 2021

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

A study, available on the pre-print server bioRxiv*, evaluated the neutralizing capacity of a fully human polyclonal antibody (SAB-185) against the Delta, Kappa, and Lambda variants using a lentiviral-based pseudovirus assay.

17 Aug 2021

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

The safety, immunogenicity, and efficacy of the vaccines in adolescents are largely unknown. Now, a new study published in the New England Journal of Medicine evaluates the safety and efficacy of the mRNA-1273 vaccine in adolescents (12-17 years of age).

16 Aug 2021

Combining inhibitor drug with immunotherapy agent improves response in cancer patients

Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center, Bloomberg~Kimmel Institute for Cancer Immunotherapy and several other centers including University of Pittsburgh Cancer Institute, Yale Cancer Center and City of Hope in Los Angeles, which participated in study enrollment, and the University of Southern California and University College Cork in Ireland, which collaborated on analysis of the data.

16 Aug 2021

World-first trial of third dose COVID-19 booster vaccine shows improved protection in transplant patients

Scientists with the Ajmera Transplant Centre at UHN have conducted a first-in-the-world randomized placebo-controlled trial of third dose COVID-19 booster vaccine for transplant patients that shows substantially improved protection.

14 Aug 2021

Study helps to clarify the post-clinical trial needs of cancer patients

Cancer clinical trials (CCTs) provide patients an opportunity to receive experimental drugs, tests, and/or procedures that can lead to remissions. For some, a CCT may seem like their only option. Yet little is known about the experiences of patient participants who withdraw from CCTs.

14 Aug 2021

UC Davis joins with Pfizer for COVID-19 booster vaccine trial

As COVID-19 booster shots begin for those with compromised immune systems, researchers at the UC Davis School of Medicine continue to collect data from clinical trial participants.

13 Aug 2021

Study finds durable responses to immunotherapy in rare angiosarcomas

In a small study of 16 patients with the rare cancer angiosarcoma, tumors in four patients partially or completely responded to treatment with a combination of the immunotherapy drugs ipilimumab and nivolumab.

13 Aug 2021

Camelid nanobody anti-SARS-CoV-2 drug candidates

In a research paper recently published in the journal eLife, researchers from several US institutions have developed a nanobody-based candidate drug that effectively prevents and suppresses severe SARS-CoV-2 infection in animals.

12 Aug 2021

Small NIH clinical trial shows that new monoclonal antibody can prevent malaria

One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in people who were exposed to the malaria parasite.

11 Aug 2021

A new promising target for broad-spectrum therapeutics against coronaviruses

A recent study by Canadian and US researchers demonstrates how frameshift signals of coronaviruses represent a viable target for developing novel therapeutics with broad-spectrum activity – not only against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also other constituents of the coronavirus family. The study is currently available on the bioRxiv* preprint server while it undergoes peer review.

11 Aug 2021

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

A new study has explored a series of potential flavonoid inhibitors targeting 3CL protease of SARS-CoV.

9 Aug 2021

Previous
1
...
45
46
47
48
49
50
51
...
1143
Next

Drug Trial News

Researchers receive $14 million grant to study the effectiveness of hydrocephalus treatment

Could soluble CD24 offer some hope against severe COVID-19?

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

New clinical trial to test third dose of COVID-19 vaccine for immunocompromised people

Antiviral strategy using synthetic peptoid has promising implications for fighting infection

Lipid-lowering drug TriCor dramatically cuts treatment time for severe COVID-19 patients

Phase I clinical study evaluates safety and pharmacokinetics of ExeVir's COVID-19 neutralizing antibody

Children’s Hospital Colorado helps prove safety and efficacy of CF treatment in younger pediatric patients

New clinical trial investigates aspirin as part of new treatment for triple negative breast cancer

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

Combining inhibitor drug with immunotherapy agent improves response in cancer patients

World-first trial of third dose COVID-19 booster vaccine shows improved protection in transplant patients

Study helps to clarify the post-clinical trial needs of cancer patients

UC Davis joins with Pfizer for COVID-19 booster vaccine trial

Study finds durable responses to immunotherapy in rare angiosarcomas

Camelid nanobody anti-SARS-CoV-2 drug candidates

Small NIH clinical trial shows that new monoclonal antibody can prevent malaria

A new promising target for broad-spectrum therapeutics against coronaviruses

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News